ClinicalTrials.gg
Active, not recruitingNCT06832371LILITHUpdated Nov 3, 2026

Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia

An observational study in Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE) and Dyslipidemia, sponsored by Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi). Active, not recruiting at 30 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Observational

How we know

Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
73
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy — 2 open to participants now, 3 under way, 1 of them phase 3. Homozygous Familial Hypercholesterolemia · Italy.

Started
2024
the only one that year
Observational
3 of 15
1 open now
Registered
14th of 15
by date
Lead sponsor
2 of 15
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)

Among the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy, this one is the only one that started in 2024, is one of 3 observational ones, and was the 14th registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

2 of the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy, or all of them as a file.
02

Study summary

This observational, multicenter, retrospective and prospective study aims to evaluate the effect of lomitapide treatment on Major Adverse Cardiovascular Events (MACE) in patients with Homozygous Familial Hypercholesterolemia (HoFH).

HoFH is a rare genetic disorder characterized by extremely high levels of LDL cholesterol (LDL-C), leading to an increased risk of early cardiovascular diseases. Lomitapide is an approved medication that lowers LDL-C levels by inhibiting microsomal triglyceride transfer protein (MTP).

The study will collect data from patients who have been treated with lomitapide for at least 12 months and will compare the incidence of MACE during the first three years of treatment with the three years before treatment initiation. The study includes data collection from multiple lipid centers across Europe.

The primary objective is to assess the impact of lomitapide on MACE, while secondary objectives include evaluating changes in lipid profiles, liver function tests, and lipid-lowering treatments.

Read the detailed description

This is a multicenter, international, long-term observational study investigating the real-world impact of lomitapide on Major Adverse Cardiovascular Events (MACE) in patients with Homozygous Familial Hypercholesterolemia (HoFH).

Study Design:

Observational, open-label, retrospective and prospective study Data will be collected from 30 lipid centers across Europe Patients will serve as their own control, with comparisons between pre-treatment (3 years before lomitapide) and post-treatment (first 3 years of lomitapide therapy) periods

Study Population:

Approximately 72 adult patients (≥18 years) diagnosed with HoFH Patients must have received lomitapide for at least 12 months Availability of 3 years of pre-treatment clinical records

Objectives:

Primary Objective: Evaluate the incidence of MACE before and after lomitapide treatment

Secondary Objectives: Assess changes in LDL-C, total cholesterol, liver function tests (ALT, AST, GGT), and lipid-lowering therapy usage (e.g., discontinuation of LDL apheresis, addition of PCSK9 inhibitors)

Endpoints:

Primary Endpoint: Change in MACE incidence over the 3-year treatment period

Secondary Endpoints: Changes in lipid levels, liver safety markers, and adherence to treatment protocols

Safety Considerations:

The study follows real-world clinical practice, with monitoring of adverse events, including liver-related safety concerns associated with lomitapide

Data will be collected in an electronic Case Report Form (eCRF) and analyzed following Good Clinical Practice (GCP) guidelines

This study aims to generate real-world evidence on the cardiovascular impact of lomitapide in HoFH patients, addressing an unmet clinical need for data on long-term outcomes.

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia (HoFH)
  • Major Adverse Cardiovascular Events (MACE)
  • Dyslipidemia

Keywords

  • Lomitapide
  • Hypercholesterolemia
  • Cardiovascular Disease
  • LDL Cholesterol
  • Lipid-Lowering Therapy
  • Lipid Metabolism Disorders
  • Atherosclerosis
  • Rare Genetic Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a clinical or genetic diagnosis of homozygous familial hypercholesterolemia (HoFH) who have been treated with lomitapide for at least 12 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age ≥18 years)
  • Clinical or genetic diagnosis of HoFH
  • Treated with lomitapide at any dosage
  • On treatment with lomitapide for at least 12 months at the time of enrollment
  • Availability of 3 years of medical records prior to lomitapide treatment to confirm MACE
  • Giving written

Exclusion criteria

Exclusion Criteria:

  • Patients who were prescribed lomitapide outside of the marketing authorization or in patients
  • Patients receiving lomitapide in clinical trials
  • Patients receiving an agent, defined as any drug or biologic agent other than lomitapide that has not received Market Authorization in the country of participation, at the time of enrolment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
73 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • HoFH Patients Treated with Lomitapide

    This cohort consists of adult patients (≥18 years) diagnosed with Homozygous Familial Hypercholesterolemia (HoFH) who have been treated with lomitapide for at least 12 months. The study will retrospectively analyze the incidence of Major Adverse Cardiovascular Events (MACE) in the three years before lomitapide treatment, and prospectively track MACE incidence during the first three years of lomitapide therapy.

06

What researchers measure

Primary outcomes

  1. Incidence of Major Adverse Cardiovascular Events (MACE) Before and After Lomitapide Treatment

    This measure will assess the incidence of MACE (including myocardial infarction, stroke, cardiovascular death, and hospitalization due to unstable angina) during the first three years of lomitapide treatment compared to the three years prior to treatment initiation. Unit of Measure: Number of events per 100 patient-years.

    Time frame: 3 years before treatment vs. 3 years during treatment

Secondary outcomes

  1. Change in LDL-Cholesterol Levels

    This measure will evaluate changes in LDL-C levels. Unit of Measure: mg/dL.

    Time frame: Baseline, 1 year, 2 years, 3 years

  2. Change in Total Cholesterol, Triglycerides, and HDL-Cholesterol

    Assess changes in total cholesterol, triglycerides, and HDL-C at 1, 2, and 3 years after lomitapide treatment initiation. Unit of Measure: mg/dL.

    Time frame: Baseline, 1 year, 2 years, 3 years

  3. Change in Triglyceride Levels

    This measure will evaluate changes in triglyceride levels. Unit of Measure: mg/dL.

    Time frame: Baseline, 1 year, 2 years, 3 years.

  4. Change in HDL-Cholesterol Levels

    This measure will evaluate changes in HDL-C levels. Unit of Measure: mg/dL.

    Time frame: Baseline, 1 year, 2 years, 3 years

  5. Liver Safety Profile - ALT Levels

    This measure will evaluate changes in alanine aminotransferase (ALT) levels. Unit of Measure: U/L.

    Time frame: Baseline, 1 year, 2 years, 3 years.

  6. Liver Safety Profile - AST Levels

    This measure will evaluate changes in aspartate aminotransferase (AST) levels. Unit of Measure: U/L.

    Time frame: Baseline, 1 year, 2 years, 3 years.

  7. Liver Safety Profile - GGT Levels

    This measure will evaluate changes in gamma-glutamyl transferase (GGT) levels. Unit of Measure: U/L.

    Time frame: Baseline, 1 year, 2 years, 3 years.

  8. Lipid-Lowering Therapy Modifications

    This measure will track changes in lipid-lowering therapies, for example the discontinuation of LDL apheresis or the introduction of evinacumab, as described in the study protocol. Unit of Measure: Number of patients with therapy modifications.

    Time frame: Baseline, 1 year, 2 years, 3 years.

Other outcomes

  1. Biomarkers of Liver and Vascular Damage

    This measure will evaluate biomarkers of liver and vascular damage, including FIB4, apolipoprotein B, lipoprotein(a), cytokeratin 18 fragment (CK-18F), hematology, and other relevant markers. Unit of Measure: Laboratory values in mg/dL or U/L, as applicable.

    Time frame: Baseline and after 3 years of lomitapide treatment.

  2. Presence and Severity of Hepatic Steatosis

    This measure will assess the presence and severity of hepatic steatosis using liver ultrasound or MRI. Severity will be graded as absent, mild, moderate, or severe. Unit of Measure: Qualitative assessment (absent, mild, moderate, severe).

    Time frame: After 3 years of lomitapide treatment.

  3. Liver Elastography Parameters

    This measure will evaluate liver elastography parameters using fibroscan or other methods. Measurements will include liver stiffness (kPa) and controlled attenuation parameter (CAP) values. Unit of Measure: kPa (kilopascal) and CAP (dB/m).

    Time frame: After 3 years of lomitapide treatment.

  4. Dietary Records

    This measure will evaluate dietary patterns using a food frequency questionnaire (FFQ) for patients participating in the prospective phase of the study. Unit of Measure: Responses to FFQ (categorical and quantitative data).

    Time frame: After 3 years of lomitapide treatment.

  5. Adherence to Lipid-Lowering Medications

    This measure will evaluate adherence to lipid-lowering medications, including lomitapide, using a Medication Adherence Scale for patients participating in the prospective phase. Unit of Measure: Medication Adherence Scale scores.

    Time frame: After 3 years of lomitapide treatment.

07

Study locations

30 sites
  • CHRU Lille - Centre Hospitalier Universitaire de Lille
    Lille, France
  • Centre Hospitalier Universitaire de Lyon (CHU Lyon)
    Lyon, France
  • Hôpital de la Conception - Assistance Publique Hôpitaux de Marseille (AP-HM)
    Marseille, France
  • Hôpital La Pitié Salpêtrière - Groupe Hospitalier "La Pitié Salpêtrière - Charles Foix"
    Paris, France
  • Strasbourg University Hospital (CHU Strasbourg)
    Strasbourg, France
  • University General Hospital of Ioannina
    Ioannina, Greece
  • METROPOLITAN HOSPITAL, Piraeus
    Piraeus, Greece
  • Policlinico di Catanzaro - A.O.U. Mater Domini
    Catanzaro, Calabria 88100, Italy
  • Ospedale Sant'Anna e San Sebastiano
    Caserta, Campania 81100, Italy
  • Policlinico Federico II di Napoli
    Naples, Campania 80131, Italy
  • Policlinico Sant'Orsola - Università di Bologna
    Bologna, Emilia-Romagna 40138, Italy
  • Arcispedale Sant'Anna - Università degli Studi di Ferrara
    Ferrara, Emilia-Romagna 44124, Italy
  • Ospedale Civile di Baggiovara - A.O.U. di Modena
    Modena, Emilia-Romagna 41124, Italy
  • DIMI - Dipartimento di Medicina Interna, Università di Genova
    Genova, GE 16132, Italy
  • ARNAS Garibaldi
    Catania, Italy, Italy
  • Policlinico Umberto I - Sapienza Università di Roma
    Rome, Lazio 00161, Italy
  • Ospedale Bassini - ASST Nord Milano
    Milan, Lombardy 20092, Italy
  • Policlinico Paolo Giaccone - Università degli Studi di Palermo
    Palermo, Sicily 90127, Italy
  • Ospedale San Luigi Gonzaga
    Orbassano, Torino 10043, Italy
  • A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette
    Torino, Torino 10126, Italy
  • CNR Gabriele Monasterio - Centro di Aferesi, Pisa
    Pisa, Tuscany 56124, Italy
  • Policlinico di Padova - A.O.U. di Padova
    Padova, Veneto 35128, Italy
  • Ospedale Borgo Trento - A.O.U. Integrata Verona
    Verona, Veneto 37126, Italy
  • Ospedale regionale generale "F. Miulli"
    Bari, Italy
  • Radboud University Medical Centre
    Nijmegen, Netherlands
  • Rotterdam Erasmus Medical Center
    Rotterdam, Netherlands
  • Queen Elizabeth Hospital Birmingham (QEII - Birmingham)
    Birmingham, England, United Kingdom
  • Harefield Hospital - Royal Brompton & Harefield NHS Foundation Trust
    Harefield, England, United Kingdom
  • Hammersmith Hospital - Imperial College Healthcare NHS Trust
    London, England W12 0HS, United Kingdom
  • Manchester University Hospital - NHS Foundation Trust
    Manchester, England, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — The LILITH study collects observational data on patients treated with lomitapide in compliance with data protection regulations (GDPR) and Good Clinical Practice (GCP) guidelines. At this time, individual participant data (IPD) sharing is not planned to ensure confidentiality and adherence to ethical and legal requirements. However, aggregated study results will be made available through scientific publications and regulatory reports.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2024 (actual). Primary completion is estimated for Feb 2028, 41 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Dec 2026 → Feb 2028 and completion Dec 2026 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 18, 2025
StartActual
Sep 9, 2024
Primary completionEst.
Feb 2028was Dec 2026
CompletionEst.
Feb 2028was Dec 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Feb 2028
Nov 3, 2026
Study completion
Dec 2026→Feb 2028
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Dec 2026→Feb 2028
    Study completion Dec 2026→Feb 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06832371
Lead sponsor
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
Collaborators
Amryt Pharmaceuticals DAC, Clinical Trial Consulting, CMV-Stat S.r.l.
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Sep 9, 2024
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion